gvtcx

250262 - Contract for Supply, Delivery, Installation & Commissioning of a Surface Plasmon Resonance (SPR) System.

Queen's University Belfast Published 15 Jan 2026 Find a Tender

key details

Value£700,000
Statuscomplete
Category (CPV) 38430000 +1 more
RegionNorthern Ireland
Deadline14 Nov 2025
Procedureopen
SME suitableYes
OCIDocds-h6vhtk-05cdd5

Award

SupplierValueDateStatus
Global Life Sciences Solutions Operations UK Limited £700,000 22 Dec 2025 active

description

The Future Medicines Institute (FMI) requires a Surface Plasmon Resonance (SPR) system with advanced capabilities for real-time, label-free analysis of biomolecular interactions.

(Maximum budget available for Equipment inclusive of 3 years extended warranty & annual preventative maintenance is is £330,000).

The primary objective of procuring an SPR device is to enhance FMI’s capacity to characterise binding kinetics, affinity, and specificity of biomolecular interactions, thereby strengthening its protein science and drug discovery workflows.

The proposed system must:

Provide precise kinetic and affinity measurements for a wide range of biomolecular interactions, including protein–protein, protein–antibody, and protein–small molecule binding.
Deliver high sensitivity and reproducibility to ensure reliable and quantitative data across experiments.
Support automation and high-throughput analysis, enabling efficient screening of large sample sets.
Include robust data analysis software for comprehensive kinetic modelling and data interpretation.
Offer versatile assay configurations, supporting various experimental formats and immobilisation chemistries.
Integrate seamlessly with upstream and downstream workflows, including protein purification and structural analysis.

The procurement of a high-performance SPR system directly supports FMI’s broader goals of:

Accelerating drug discovery through rapid identification and characterisation of therapeutic candidates.
Enhancing biopharmaceutical research by enabling detailed analysis of binding mechanisms critical to biologics development.
Facilitating translational research by bridging fundamental molecular interaction studies with clinical and therapeutic applications.

This procurement will provide direct benefit to research scientists by:

Reducing manual intervention and experimental variability through automation and streamlined workflows.
Enhancing data quality with high-resolution detection and advanced signal processing for accurate kinetic profiling.
Please note: - The execution of this tender & contract will be solely dependent on grant funding being received, which is estimated to be confirmed in November 2025.
No award will be made, or orders issued until the grant funding has been confirmed. If grant funding is not secured, the market will be notified, and this procurement exercise will be stood down.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

6 notices published against this procurement.

PublishedTypeRegimeNotice
16 Oct 2025 Preliminary market engagement (UK2) Procurement Act 2023 065844-2025
17 Oct 2025 Tender notice (UK4) Procurement Act 2023 066106-2025
27 Oct 2025 Tender notice (UK4) Procurement Act 2023 068436-2025
10 Nov 2025 Tender notice (UK4) Procurement Act 2023 072246-2025
22 Dec 2025 Contract award (UK6) Procurement Act 2023 085607-2025
15 Jan 2026 Contract details (UK7) Procurement Act 2023 003495-2026

more from Queen's University Belfast

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.